(Q24603112)

health care outcome assessment

9 July 2024

1 reference

7 August 2019

1 reference

19 September 2019

1 reference

9 September 2020

1 reference

4 November 2020

1 reference

23 December 2020

1 reference

8 February 2021

cell-mediated immunity

1 reference

Alexander M. M. Eggermont

author

2

object named as

Alexander M M Eggermont

0 references

Jedd D. Wolchok

10

object named as

Jedd Wolchok

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20826737

9 July 2024

4

F Stephen Hodi

0 references

Lloyd J. Old

9

object named as

Lloyd Old

0 references

author name string

Axel Hoos

1

0 references

Sylvia Janetzki

3

0 references

Ramy Ibrahim

5

0 references

Aparna Anderson

6

0 references

Rachel Humphrey

7

0 references

Brent Blumenstein

8

0 references

Alexander M. M. Eggermont

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20826737

9 July 2024

Lloyd Old

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20826737

9 July 2024

language of work or name

English

0 references

publication date

22 September 2010

11 references

3 April 2019

20 June 2019

19 June 2019

22 June 2019

25 June 2019

7 August 2019

19 September 2019

9 September 2020

4 November 2020

23 December 2020

8 February 2021

8 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20826737

full work available at URL

9 July 2024

https://academic.oup.com/jnci/article-pdf/102/18/1388/17984850/djq310.pdf

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20826737

http://jncicancerspectrum.oxfordjournals.org/cgi/content/abstract/102/18/1388

9 July 2024

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20826737

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20826737/?tool=EBI

9 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20826737

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/20826737/pdf/?tool=EBI

9 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20826737

https://europepmc.org/articles/PMC2943524

9 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20826737

https://europepmc.org/articles/PMC2943524?pdf=render

9 July 2024

online access status

open access

content deliverer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20826737

http://academic.oup.com/jnci/article-pdf/102/18/1388/17984850/djq310.pdf

9 July 2024

1 reference

Journal of the National Cancer Institute

9 July 2024

published in

11 references

3 April 2019

20 June 2019

19 June 2019

22 June 2019

25 June 2019

7 August 2019

19 September 2019

9 September 2020

4 November 2020

23 December 2020

8 February 2021

102

0 references

issue

18

0 references

page(s)

1388-97

0 references

copyright license

Creative Commons Attribution-NonCommercial

11 references

3 April 2019

20 June 2019

19 June 2019

22 June 2019

25 June 2019

7 August 2019

19 September 2019

9 September 2020

4 November 2020

23 December 2020

8 February 2021

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Cancer immunotherapy: moving beyond current vaccines

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Idiotype vaccines for lymphoma: proof-of-principles and clinical trial failures

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Improving the efficacy of cancer immunotherapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC).

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Toward the harmonization of immune monitoring in clinical trials: quo vadis?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI)

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Immunostimulatory monoclonal antibodies for cancer therapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

A clinical development paradigm for cancer vaccines and related biologics

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Validation overview of bio-analytical methods

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Current developments in cancer vaccines and cellular immunotherapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Monitoring immune responses in cancer patients receiving tumor vaccines

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Immunologic monitoring of cancer vaccine therapy: results of a workshop sponsored by the Society for Biological Therapy.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

"MIATA"-minimal information about T cell assays

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Sample Sizes Based on the Log-Rank Statistic in Complex Clinical Trials

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2943524

Enumerating antigen-specific T-cell responses in peripheral blood: a comparison of peptide MHC Tetramer, ELISpot, and intracellular cytokine analysis.

30 May 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ310

Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ310

Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ310

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ310

New response criteria proposed for immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ310

Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ310

Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ310

A partially grouped logrank test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ310

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ310

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJQ310

Developing Immunotherapy As Legitimate Therapy for Patients With Prostate Cancer

21 January 2018

1 reference

12 December 2020

Measuring response in a post-RECIST world: from black and white to shades of grey

1 reference

12 December 2020

Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure

1 reference

12 December 2020

Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma

1 reference

12 December 2020

1 reference

12 December 2020

Journal of Clinical Oncology

14

25

18s

2007

1 reference

Journal of Clinical Oncology

9 July 2024

15

26

19s

2008

1 reference

Journal of Clinical Oncology

9 July 2024

38

26

19s

2008

1 reference

9 July 2024

Identifiers

DOI

10.1093/JNCI/DJQ310

1 reference

1 reference

1 reference

1 reference